Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

9.9%

7 terminated/withdrawn out of 71 trials

Success Rate

87.7%

+1.2% vs industry average

Late-Stage Pipeline

34%

24 trials in Phase 3/4

Results Transparency

48%

24 of 50 completed trials have results

Key Signals

10 recruiting24 with results6 terminated

Enrollment Performance

Analytics

N/A
18(27.7%)
Phase 3
15(23.1%)
Phase 2
12(18.5%)
Phase 1
11(16.9%)
Phase 4
9(13.8%)
65Total
N/A(18)
Phase 3(15)
Phase 2(12)
Phase 1(11)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (71)

Showing 20 of 71 trials
NCT06891443Phase 3Recruiting

Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION)

Role: lead

NCT07234318Active Not Recruiting

A Non-interventional Study to Evaluate the Anti-inflammatory Effects and the Clinical Efficacy of Topical Water Free Cyclosporin 0.1% Eye Drops in Patients With Dry Eye Disease and Associated Ocular Surface Inflammation Non-responding to Artificial Tears: the FOCUS Study

Role: lead

NCT07234292Recruiting

Evaluation of Patient Satisfaction With Blephaderm as a Complementary Care in Post-eyelid Surgery

Role: lead

NCT07169695Phase 2Recruiting

A Study to Compare the Effectiveness and Safety of T1695 Versus Ciclosporin in Participants With Moderate to Severe Vernal Keratoconjunctivitis

Role: lead

NCT07522242Phase 2Recruiting

Safety and Efficacy of T10430 Eye Drops in Controlling Paediatric Myopia Progression

Role: lead

NCT06627179Phase 2Recruiting

Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene

Role: lead

NCT05965778Not ApplicableCompleted

Performance and Safety of T2769 in DED

Role: lead

NCT06394973Phase 2Completed

Efficacy and Safety Assessment of T4090 Ophthalmic Solution Versus Rhopressa® Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension

Role: lead

NCT06375499Not ApplicableCompleted

Performance and Safety of T2769 Versus Hylo-Forte® in the Treatment of Moderate to Severe Dry Eye Syndrome.

Role: lead

NCT04499820Not ApplicableCompleted

Effect of OMEGA3 Supplementation in Diabetic Retinopathy

Role: collaborator

NCT06903741Phase 4Recruiting

New Preservative-free Combination of Trehalose, Sodium Hyaluronate and N-acetyl-aspartyl-glutamate (NAAGA) in Dry Eye

Role: lead

NCT07206628Recruiting

Real-world Study to Assess Adherence to IOP Lowering Therapy in Glaucoma Patients Using CONNECTDROP®

Role: lead

NCT07007702Completed

Anti-inflammatory Effects and Clinical Efficacy of Topical Thealoz Total Eye Drops in Patients With Chronic Dry Eye Disease

Role: lead

NCT05668455Phase 3Recruiting

Comparison of Topical Treatment for Inflammatory Secretions of the Conjonctiva (Patients With Ocular Prostheses)

Role: collaborator

NCT05931861Not ApplicableCompleted

Performance and Safety Assessment of T2769 in Contact Lens Wearers With Dry Eye Symptoms.

Role: lead

NCT03913130Phase 1Terminated

Extension Study to Study PQ-110-001 (NCT03140969)

Role: lead

NCT03140969Phase 1Completed

Study to Evaluate QR-110 in Leber's Congenital Amaurosis (LCA) Due to the c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 Gene

Role: lead

NCT05085964Phase 2Terminated

An Open-Label Extension Study to Evaluate Safety & Tolerability of QR-421a in Subjects With Retinitis Pigmentosa

Role: lead

NCT05176717Phase 2Terminated

Study to Evaluate the Efficacy Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene With Early to Moderate Vision Loss (Celeste)

Role: lead

NCT05397600Phase 3Completed

Efficacy and Safety Assessment of T4032 (Unpreserved Bimatoprost 0.01%) Versus Lumigan® 0.01% in Ocular Hypertensive or Glaucomatous Patients

Role: lead